NASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free PRCT Stock Alerts $51.19 +1.00 (+1.99%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$50.02▼$52.1250-Day Range$45.73▼$53.3252-Week Range$24.83▼$54.50Volume478,997 shsAverage Volume497,207 shsMarket Capitalization$2.61 billionP/E RatioN/ADividend YieldN/APrice Target$45.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get PROCEPT BioRobotics alerts: Email Address PROCEPT BioRobotics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside10.9% Downside$45.60 Price TargetShort InterestBearish9.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 2 Articles This WeekInsider TradingSelling Shares$4.65 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.00) to ($1.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.56 out of 5 starsMedical Sector857th out of 909 stocksSurgical & Medical Instruments Industry91st out of 97 stocks 1.5 Analyst's Opinion Consensus RatingPROCEPT BioRobotics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePROCEPT BioRobotics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.58% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in PROCEPT BioRobotics has recently increased by 12.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRCT. Previous Next 2.6 News and Social Media Coverage News SentimentPROCEPT BioRobotics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PROCEPT BioRobotics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for PRCT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,653,720.00 in company stock.Percentage Held by Insiders19.60% of the stock of PROCEPT BioRobotics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($2.00) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -22.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -22.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 9.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About PROCEPT BioRobotics Stock (NASDAQ:PRCT)PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Read More PRCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRCT Stock News HeadlinesApril 16, 2024 | americanbankingnews.comContrasting SeaStar Medical (NASDAQ:ICU) & PROCEPT BioRobotics (NASDAQ:PRCT)April 13, 2024 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Sets New 12-Month High at $53.54April 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 8, 2024 | msn.comExperts Top 5 AI Stocks With Huge PotentialApril 4, 2024 | globenewswire.comPROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, TexasApril 2, 2024 | globenewswire.comPROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024March 20, 2024 | finance.yahoo.comPROCEPT BioRobotics Corp (PRCT) President and CEO Reza Zadno Sells Company SharesMarch 18, 2024 | finance.yahoo.comPRCT Oct 2024 55.000 callApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 16, 2024 | ca.finance.yahoo.comPRCT Apr 2024 50.000 putMarch 8, 2024 | finance.yahoo.comEVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics Corp (PRCT)March 7, 2024 | finance.yahoo.comDirector Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)March 1, 2024 | nasdaq.comNoteworthy Wednesday Option Activity: ZM, PRCT, MSTRMarch 1, 2024 | finance.yahoo.comPROCEPT BioRobotics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsFebruary 29, 2024 | ca.finance.yahoo.comPRCT Jul 2024 70.000 callFebruary 29, 2024 | ca.finance.yahoo.comPRCT Mar 2024 70.000 callFebruary 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX) and Viridian Therapeutics (VRDN)February 28, 2024 | markets.businessinsider.comTruist Securities Maintains Buy Rating for PROCEPT BioRobotics: Here's What You Need To KnowFebruary 28, 2024 | finance.yahoo.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comQ4 2023 Procept Biorobotics Corp Earnings CallFebruary 28, 2024 | investors.comBio Stock Procept BioRobotics Eyes Rare Buy Trigger After EarningsFebruary 27, 2024 | seekingalpha.comPROCEPT BioRobotics Corporation 2023 Q4 - Results - Earnings Call PresentationFebruary 27, 2024 | benzinga.comPROCEPT BioRobotics: Q4 Earnings InsightsFebruary 27, 2024 | globenewswire.comPROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 ResultsFebruary 26, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)February 26, 2024 | benzinga.comPROCEPT BioRobotics's Earnings: A PreviewFebruary 24, 2024 | thestreet.comPROCEPT BioRobotics CorporationSee More Headlines Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/23/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PRCT CUSIPN/A CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees626Year FoundedN/APrice Target and Rating Average Stock Price Target$45.60 High Stock Price Target$58.00 Low Stock Price Target$37.00 Potential Upside/Downside-10.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,900,000.00 Net Margins-77.75% Pretax Margin-77.76% Return on Equity-46.59% Return on Assets-30.63% Debt Debt-to-Equity Ratio0.18 Current Ratio7.63 Quick Ratio6.77 Sales & Book Value Annual Sales$136.19 million Price / Sales19.16 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book9.21Miscellaneous Outstanding Shares50,964,000Free Float40,975,000Market Cap$2.61 billion OptionableOptionable Beta1.01 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Reza Zadno Ph.D. (Age 69)President, CEO & Director Comp: $1.26MMr. Kevin Waters (Age 47)Executive VP & CFO Comp: $744.1kMs. Alaleh Nouri (Age 45)EVP, Chief Legal Officer & Corporate Secretary Comp: $713.61kMr. Hisham Shiblaq (Age 48)Executive VP & Chief Commercial Officer Comp: $757.2kMr. Mohan F. Sancheti (Age 60)Senior Vice President of Operations Mr. Barry TemplinExecutive VP of Technology & Clinical DevelopmentMr. Matthew James Bacso C.F.A.Vice President of Investor RelationsMs. Stacey L. Porter (Age 48)Chief People Officer Mr. Bijesh ChandranSenior Vice President of Regulatory Affairs & Quality AssuranceMore ExecutivesKey CompetitorsIntegra LifeSciencesNASDAQ:IARTICU MedicalNASDAQ:ICUIInari MedicalNASDAQ:NARITandem Diabetes CareNASDAQ:TNDMiRhythm TechnologiesNASDAQ:IRTCView All CompetitorsInsiders & InstitutionsTaylor Frigon Capital Management LLCSold 39,020 shares on 4/19/2024Ownership: 0.162%Allspring Global Investments Holdings LLCBought 37,179 shares on 4/18/2024Ownership: 0.391%Diversified Trust CoBought 2,725 shares on 4/18/2024Ownership: 0.026%Fairman Group LLCBought 2,000 shares on 3/26/2024Ownership: 0.004%Reza ZadnoSold 5,391 sharesTotal: $263,242.53 ($48.83/share)View All Insider TransactionsView All Institutional Transactions PRCT Stock Analysis - Frequently Asked Questions Should I buy or sell PROCEPT BioRobotics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRCT shares. View PRCT analyst ratings or view top-rated stocks. What is PROCEPT BioRobotics' stock price target for 2024? 6 equities research analysts have issued 12-month target prices for PROCEPT BioRobotics' shares. Their PRCT share price targets range from $37.00 to $58.00. On average, they anticipate the company's share price to reach $45.60 in the next twelve months. This suggests that the stock has a possible downside of 10.9%. View analysts price targets for PRCT or view top-rated stocks among Wall Street analysts. How have PRCT shares performed in 2024? PROCEPT BioRobotics' stock was trading at $41.91 at the beginning of 2024. Since then, PRCT stock has increased by 22.1% and is now trading at $51.19. View the best growth stocks for 2024 here. When is PROCEPT BioRobotics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our PRCT earnings forecast. How can I listen to PROCEPT BioRobotics' earnings call? PROCEPT BioRobotics will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Co. (NASDAQ:PRCT) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.10. The firm earned $43.58 million during the quarter, compared to analysts' expectations of $41.79 million. PROCEPT BioRobotics had a negative trailing twelve-month return on equity of 46.59% and a negative net margin of 77.75%. The business's revenue was up 83.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.56) EPS. What ETFs hold PROCEPT BioRobotics' stock? ETFs with the largest weight of PROCEPT BioRobotics (NASDAQ:PRCT) stock in their portfolio include Innovator IBD 50 ETF (FFTY), SPDR S&P Health Care Equipment ETF (XHE), Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ), ALPS Disruptive Technologies ETF (DTEC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Small Cap Growth AlphaDEX Fund (FYC), Principal Healthcare Innovators ETF (BTEC) and BNY Mellon Innovators ETF (BKIV). What guidance has PROCEPT BioRobotics issued on next quarter's earnings? PROCEPT BioRobotics updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $210.0 million-$210.0 million, compared to the consensus revenue estimate of $204.5 million. When did PROCEPT BioRobotics IPO? PROCEPT BioRobotics (PRCT) raised $126 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share. Who are PROCEPT BioRobotics' major shareholders? PROCEPT BioRobotics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.39%), Taylor Frigon Capital Management LLC (0.16%) and Diversified Trust Co (0.03%). Insiders that own company stock include Alaleh Nouri, Frederic H Moll, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRCT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.